Taglich Brothers Weighs in on Zynex Inc.’s Q4 2017 Earnings (ZYXI)
Zynex Inc. (OTCMKTS:ZYXI) – Equities researchers at Taglich Brothers upped their Q4 2017 EPS estimates for Zynex in a research note issued on Monday. Taglich Brothers analyst H. Halpern now forecasts that the company will earn $0.08 per share for the quarter, up from their previous estimate of $0.02. Taglich Brothers currently has a “Speculative Buy” rating on the stock. Taglich Brothers also issued estimates for Zynex’s Q1 2018 earnings at $0.08 EPS.
Zynex (OTCMKTS:ZYXI) last issued its quarterly earnings data on Monday, November 13th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. Zynex had a net margin of 24.10% and a negative return on equity of 248.78%. The business had revenue of $6.82 million during the quarter, compared to analysts’ expectations of $5.52 million. COPYRIGHT VIOLATION NOTICE: “Taglich Brothers Weighs in on Zynex Inc.’s Q4 2017 Earnings (ZYXI)” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/taglich-brothers-weighs-in-on-zynex-inc-s-q4-2017-earnings-zyxi/1723334.html.
ZYXI has been the subject of a number of other reports. ValuEngine cut shares of Zynex from a “buy” rating to a “hold” rating in a research note on Tuesday, October 31st. Zacks Investment Research raised shares of Zynex from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a research note on Thursday.
Zynex (OTCMKTS:ZYXI) opened at $3.04 on Thursday. Zynex has a 52 week low of $0.25 and a 52 week high of $3.25. The company has a market cap of $99.81, a price-to-earnings ratio of 23.39 and a beta of -0.03. The company has a quick ratio of 1.19, a current ratio of 1.27 and a debt-to-equity ratio of 0.02.
Zynex, Inc operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation.
Receive News & Ratings for Zynex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.